Multiple-mechanism-of-action protein targets enable us to develop novel therapies for inflammatory diseases.
Our focus is on those devastating diseases which currently have no effective treatment, cause suffering to millions of patients and their families and cost society billions of dollars.
ARDS is an acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. In ARDS, fluid leaks into lungs making it difficult to absorb oxygen and the patient cannot breathe
GEn1E’s team, led by Dr. Ritu Lal, has decades of experience working on drug development and platform technologies
We have a ML platform for efficient development of Novel and NextGen Selective Immunomodulatory Therapies
This includes a rich pipeline of novel immunomodulators for various indications
Our founder and team have decades of domain expertise in research, machine learning and clinical development
In 2+ years with seed financing, we have developed 21+ novel compounds with a Lead Compound in the Clinical-stage
Curated database includes GEn1E generated proprietary data for our drugs as well curated data for inflammatory and rare diseases
Each inflammatory disease has its own unique signature as expressed with multiple biomarkers. The platform matches our drug’s unique signature with the inflammatory disease signature to select the best match of our drug for the disease
We utilize a continuous feedback loop across the entire process from discovery to clinical studies.
Neural Networks, Gradient Boosting Methods and Hidden Markov Models are used to accelerate drug development
The founding CEO, Dr. Ritu Lal, has taken drugs from discovery through FDA approval 3 times. She has formed a world-class team, which includes stellar Advisors and many of the world’s top ARDS experts